WHO pauses hydroxychloroquine trial over safety concerns
CORONAVIRUS | The World Health Organization has suspended testing the malaria drug hydroxychloroquine in Covid-19 patients due to safety concerns, WHO director-general Tedros Adhanom Ghebreyesus said on Monday.
The World Health Organization said on Monday that it has suspended its trial of the malaria drug hydroxychloroquine in Covid-19 patients due to safety concerns.
CORONAVIRUS | The World Health Organization has suspended testing the malaria drug hydroxychloroquine in Covid-19 patients due to safety concerns, WHO director-general Tedros Adhanom Ghebreyesus said on Monday.
The World Health Organization said on Monday that it has suspended its trial of the malaria drug hydroxychloroquine in Covid-19 patients due to safety concerns.
Malaysia is one of the countries recruited by the WHO to be part of the trial.
Hydroxychloroquine has been touted by US President Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus.
Earlier this month, Trump said he was taking the drug to ward off the virus.
"Yeah, I'm taking it."
WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
The decision to pause the trial was done out of an abundance of caution while safety data is reviewed.
WHO said that other arms of the so-called "Solidarity trial" - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
- Reuters
Are you sure you want to delete this comment?
This action cannot be undone.